Autopsy report · NCT01724619

Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT

“Study tracer can no longer be obtained at our institution”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 months before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Wake Forest University Health Sciences

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

[F-18] fluorinated dihydrotestosterone (FDHT)

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
  “Study was terminated due to lack of accrual” (59% match in meaning)
• Dissociation Investigation Study in Sex Offenders
  “STUDY INVESTIGATORS HAVE LEFT THE INSTITUTION, THE DEPARTMENT NO LONGER HAS TIME TO INCLUDE” (59% match in meaning)
• Randomized Controlled Trial (RCT) Umbilical Hernia Repair (UHR) Absorbable vs Non-absorbable Synthetic Mesh
  “study was never opened and PI now leaving institution” (58% match in meaning)
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
  “Study terminated due to slow/insufficient accrual.” (58% match in meaning)
• Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
  “Study was terminated due to administrative reasons” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.